PDF(Pubmed)
Abstract：
Synbiotics are increasingly used by the general population to boost immunity. However, there is limited evidence concerning the immunomodulatory effects of synbiotics in healthy individuals. Therefore, we conducted a double-blind, randomized, placebo-controlled study in 106 healthy adults. Participants were randomly assigned to receive either synbiotics (containing Bifidobacterium lactis HN019 1.5 × 108 CFU/d, Lactobacillus rhamnosus HN001 7.5 × 107 CFU/d, and fructooligosaccharide 500 mg/d) or placebo for 8 weeks. Immune parameters and gut microbiota composition were measured at baseline, mid, and end of the study. Compared to the placebo group, participants receiving synbiotic supplementation exhibited greater reductions in plasma C-reactive protein (P = 0.088) and interferon-gamma (P = 0.008), along with larger increases in plasma interleukin (IL)-10 (P = 0.008) and stool secretory IgA (sIgA) (P = 0.014). Additionally, synbiotic supplementation led to an enrichment of beneficial bacteria (Clostridium_sensu_stricto_1, Lactobacillus, Bifidobacterium, and Collinsella) and several functional pathways related to amino acids and short-chain fatty acids biosynthesis, whereas reduced potential pro-inflammatory Parabacteroides compared to baseline. Importantly, alternations in anti-inflammatory markers (IL-10 and sIgA) were significantly correlated with microbial variations triggered by synbiotic supplementation. Stratification of participants into two enterotypes based on pre-treatment Prevotella-to-Bacteroides (P/B) ratio revealed a more favorable effect of synbiotic supplements in individuals with a higher P/B ratio. In conclusion, this study suggested the beneficial effects of synbiotic supplementation on immune parameters, which were correlated with synbiotics-induced microbial changes and modified by microbial enterotypes. These findings provided direct evidence supporting the personalized supplementation of synbiotics for immunomodulation.
摘要：
普通人群越来越多地使用合生元来提高免疫力。然而,关于合生元对健康个体的免疫调节作用的证据有限。因此,我们进行了双盲，随机化，106名健康成年人的安慰剂对照研究。参与者被随机分配接受合生元（含有乳酸双歧杆菌HN0191.5×108CFU/d，鼠李糖乳杆菌HN0017.5×107CFU/d,和低聚果糖500毫克/天）或安慰剂8周。免疫参数和肠道菌群组成在基线测量，mid,研究结束。与安慰剂组相比，接受合生元补充的参与者显示血浆C反应蛋白(P=0.088)和干扰素-γ(P=0.008)降低幅度更大,随着血浆白细胞介素（IL）-10（P=0.008）和粪便分泌型IgA（sIgA）（P=0.014）的增加。此外,合生元的补充导致有益细菌的富集(梭状芽孢杆菌_sensu_stricto_1，乳杆菌，双歧杆菌,和Collinsella）以及与氨基酸和短链脂肪酸生物合成相关的几种功能途径，而与基线相比，潜在的促炎副杆菌减少。重要的是,抗炎标志物(IL-10和sIgA)的改变与合生元补充引发的微生物变异显著相关.根据治疗前的Prevotella与拟杆菌（P/B）比率将参与者分为两种肠型，这表明合生元补充剂在P/B比率较高的个体中具有更有利的作用。总之,这项研究表明，合生元补充对免疫参数的有益作用，与合生元诱导的微生物变化相关，并被微生物肠型修饰。这些发现提供了直接的证据支持合生元的个性化补充用于免疫调节。
